NPCE — NeuroPace Inc

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1528287 ·
Last close
$8.20
Market Cap
$282.50M
52W High
$19.60
52W Low
$5.46
ADV30
391,617
Next earnings
2026-11-12
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 23,104,000 19,471,000 -2,080,000 -3,298,000 94,775,000 10,235,000 83,283,000
Jun 2026 22,826,000 18,906,000 -5,143,000 -6,200,000 96,991,000 12,538,000 85,108,000
Mar 2026 22,068,000 18,048,000 -5,568,000 -6,689,000 98,898,000 14,779,000 84,444,000
Dec 2025 26,588,000 20,578,000 -1,767,000 -2,729,000 105,565,000 21,692,000 86,534,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,241,000
Investing CF
$-369,000
Financing CF
$1,410,000
CapEx
$-369,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.57
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-565,304,000
Inventory
$18,111,000
Receivables
$14,930,000
ST Investments
$39,161,000
EBIT TTM
$-12,809,000
Pretax Income TTM
$-19,114,000
Interest Exp TTM
$6,305,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$106,746,000
EBITDA
$-9,906,000
Free Cash Flow
$-2,411,625
Enterprise Value
$280,762,880
Total Cash
$49,231,000
Total Debt
$69,540,000
Shares Out
34,451,570
Trailing EPS
$-0.56
Book Value
$0.33
ROE
-97.0%
ROA
-6.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 99,986,000 -16,338,000 -21,465,000 105,565,000 86,534,000 19,031,000 -11,006,000
Dec 2024 79,906,000 -21,671,000 -27,141,000 94,647,000 86,634,000 8,013,000 -17,949,000
Dec 2023 65,421,000 -27,174,000 -32,956,000 107,651,000 86,997,000 20,654,000 -19,701,000
Dec 2022 45,520,000 -40,794,000 -47,082,000 114,106,000 79,329,000 34,777,000 -36,869,000

TTM Snapshot

Revenues TTM
$98,836,000
NetIncome TTM
$-19,114,000
OpCashFlow TTM
—
Assets (Latest)
$96,991,000
Forward EPS
$-0.30

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $8.22 · call volume: 113 · put volume: 17
Expected Move to 2026-12-18: ±$1.37 (16.67%) — implied range $6.85 – $9.59 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TMCI TREACE MEDICAL CONCEPTS, INC. $288.75M $4.44 —
OFIX Orthofix Medical Inc. $271.87M $6.67 —
INFU InfuSystem Holdings, Inc $296.30M $14.79 —
SSII SS Innovations International, Inc. $266.51M $1.33 —
SMTI Sanara MedTech Inc. $300.55M $32.73 —

News headlines (Yahoo Finance, 1h cache)

Is NPCE Worth Buying Now as Growth Potential Meets Execution Risk?
2026-11-17 15:48 · Yahoo
NeuroPace (NPCE) Stock Fair Value Falls After Analysts Cut Targets On Q3 Miss
2026-11-16 12:10 · Yahoo
NeuroPace, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
NeuroPace (NPCE) Q3 2026 Earnings Call Transcript
2026-11-13 05:43 · Yahoo
What NeuroPace (NPCE) Said on Its Q3 Earnings Call
2026-11-13 04:14 · Yahoo
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 21:25 · Yahoo
NeuroPace Inc.: Q3 Earnings Snapshot
2026-11-12 21:13 · Yahoo
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-10-29 20:05 · Yahoo
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
2026-09-10 15:30 · Yahoo
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
2026-09-04 13:58 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-17 17:08:22 2026-11-17 Becker Joel CEO P - Purchase 8.35 11891 99293
2026-11-17 17:10:42 2026-11-17 Williams Patrick F. CFO P - Purchase 8.34 11891 99148